zafirlukast


Also found in: Medical, Wikipedia.

za·fir·lu·kast

 (zə-fîr′lo͞o-kăst′)
n.
A drug, C31H33N3O6S, that acts as a leukotriene receptor antagonist, reduces the inflammatory process, and is used in the treatment of asthma.

[zafir- (perhaps ultimately alteration of sulfonyl) + -lukast, leukotriene receptor antagonist suff. (from rearrangement of (anti)as(thmatic) l(e)uk(otriene receptor antagonis)t).]
Translations

zafirlukast

n zafirlukast m
Mentioned in ?
References in periodicals archive ?
Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.
To clarify which receptor was mediating the most of the cardiovascular CysLT effects, the consequences of the HAMI3379 and zafirlukast, [CysLT.sub.2]R and [CysLT.sub.1]R antagonists, respectively, were tested on LTC4-treated, Langendorff-perfused, guinea pig hearts [139].
Cysteinyl LT receptor antagonists such as Zafirlukast and montelukast are advocated for the treatment of bronchial asthma.
[USPRwire, Tue Sep 06 2016] The '2016 Zafirlukast Industry Market Report' is a professional and in-depth study on the current state of the global Zafirlukast industry with a focus on the Chinese market.
(33) who demonstrated that while montelukast, MK571 and zafirlukast (inverse agonists of [CysLT.sub.1]R) increase, LTD4 decreases cell surface receptor expression in COS-7 cells.
Type 2 lepra reaction/ENL is an immune complex mediated response, hence corticosteroids, thalidomide, clofazimine, methotrexate, pentoxifylline, cyclosporine, azathioprine, zafirlukast, infliximab, etanercept, colchicine, chloroquine, and oral zinc have been found to be useful treatment options.
Australian drug development company Invion Limited, has secured a commitment from Hovione Scientia Limited, an international pharmaceutical company expert in inhalation development and manufacturing, to progress development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.
(12) A study by Silverman et al., (13) evaluated the effects of another LTRA, zafirlukast. They randomized patients into three groups; oral zafirlukast at 20mg and 160mg vs.
Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes.
(P-14) Zafirlukast release from electrospun rubbery fiber mats.
Like zafirlukast, montelukast is a competitive antagonist for the cysteinyl leukotrienes.